Stocks · News reference
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cardiol Therapeutics Inc. has entered into a sales agreement with Jefferies LLC to establish an at-the-market (ATM) equity offering program for up to US$75 million in common shares.
Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance."A blinded review of events in MAVERIC patients
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today